Routine echocardiography in the management of stroke and transient ischaemic attack: a systematic review and economic evaluation

Michael Holmes,* John Rathbone, Chris Littlewood, Andrew Rawdin, Matt Stevenson, John Stevens, Rachel Archer, Pippa Evans and Jenny Wang

School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

*Corresponding author

Declared competing interests of authors: none

Published March 2014
DOI: 10.3310/hta18160

Scientific summary

Management of stroke and TIA
Health Technology Assessment 2014; Vol. 18: No. 16
DOI: 10.3310/hta18160

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Stroke is a major cause of mortality in the UK. As a single cause of death, stroke is second only to coronary heart disease and it can cause a range of disabilities including speech problems, limb paralysis and dementia. Approximately half of all those affected by stroke are dependent on others for help with daily activities. A transient ischaemic attack (TIA) produces symptoms similar to those of a stroke but these symptoms resolve within 24 hours and usually within a few hours. One-fifth of patients who have experienced a TIA will later develop a stroke. Identification of the underlying cause of stroke and TIA is important so that preventative therapy can be used to reduce the risk of recurrence. The causes of stroke vary although it is thought that about 20% of ischaemic strokes are cardioembolic. Transthoracic echocardiography (TTE) is a diagnostic tool used to identify cardiac sources of stroke by using sound waves to produce images of the heart, facilitating the detection of blood clots, valvular disorders and structural defects associated with stroke. TTE can be performed in fundamental imaging mode (TTEf), which uses the reflected echoes from the same spectral band as that of the emitted pulse, or in second harmonic imaging mode (TTEh), which employs the second harmonic of the emitted frequency band to construct images. Transoesophageal echocardiography (TOE) uses similar sound wave technology to produce images of the heart; however, with TOE the ultrasound transducer, positioned on an endoscope, is guided down the patient’s throat into the oesophagus. TOE is therefore more invasive than TTE but provides images without interference from the ribs or lungs.

Objectives

The overall aim was to use secondary research methods to determine the most appropriate echocardiography diagnostic management strategy for first-episode diagnosed stroke and TIA patients. More specifically, the objectives were to:

- undertake systematic reviews to determine (a) the prevalence of potential cardiac sources of stroke and TIA and (b) the diagnostic accuracy of echocardiography
- undertake a survey to describe current practice in the NHS in terms of guidelines and management strategies used by stroke centres
- evaluate the cost-effectiveness of the addition of TTE to the routine assessment of patients who have had a first-episode diagnosed stroke or TIA in the UK.

Methods

A systematic review was undertaken to identify the prevalence rates of cardiac sources of stroke and TIA in patients with first-episode ischaemic stroke or TIA. Major databases including EMBASE, MEDLINE and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) were searched from inception to December 2010 and prevalence ranges were reported. In addition, diagnostic accuracy studies of sources of stroke that are not clinically apparent on routine examination were sought in MEDLINE, EMBASE, CINAHL, PsycINFO, Web of Science, The Cochrane Library (including the Cochrane Central Register of Controlled Trials and the Database of Abstracts of Reviews of Effects), the NHS Economic Evaluation Database and the Health Technology Assessment database (from inception to September 2011). Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) checklist. Included studies were meta-analysed using WinBUGS, using a bivariate normal model to calculate the logit sensitivities and specificities in each study to account for correlation within studies.
For the economic analysis a discrete event decision-analytic model was developed to estimate the costs and quality-adjusted life-years (QALYs) accrued by each potential echocardiography strategy in the management of stroke and TIA. The model took a lifetime horizon and the perspective of the NHS. Costs and health benefits were discounted at an annual rate of 3.5% as recommended by the National Institute for Health and Care Excellence. Utility values were identified by a literature review. Univariate and probabilistic sensitivity analyses were conducted. The only pathology for which evidence was found to enable modelling was left atrial thrombus. The cost-effectiveness of echocardiography is therefore based on all stroke patients being tested (apart from those contraindicated echocardiography) but only those with a left atrial thrombus receiving the benefits and harms of treatment. The benefits of early detection of left atrial thrombi were modelled using literature reviews to estimate the diagnostic accuracy of TTEh and TOE, the benefits and harms of treatment and the risks of stroke in treated and untreated patients with and without left atrial thrombi. Hospital and long-term care costs were estimated for each strategy and each stroke outcome. The analysis was conducted for patients aged 45, 55 and 65 years and the costs and QALYs accrued for each cohort were estimated for each diagnostic strategy.

To describe current NHS stroke management practice we provided a questionnaire survey to the lead clinician of all stroke units in the UK.

Results

The searches identified 17,278 citations for the systematic review of the prevalence of potential cardiac sources of stroke and TIA, of which 65 studies were included. From the studies retrieved, TOE (45 studies) was the most frequently reported diagnostic tool used to assess cardiac pathologies followed by TTE (38 studies of TTEh and TTEf). The prevalence rates of the identified pathologies in the selected study populations were wide-ranging. From the studies identified, patent foramen ovale (PFO) was the most frequently reported pathology (39 studies) with a prevalence ranging from 0.25% to 73%, followed by atrial septal aneurysm (28 studies) with a prevalence ranging from 0.4% to 28% and mitral valve prolapse (17 studies) with a prevalence ranging from 0% to 31.6%.

The searches identified 16,504 citations for the systematic review of the diagnostic accuracy of echocardiography, of which 51 studies were included. The pooled sensitivity to detect left atrial thrombus in three studies using TTEf was 0.34 [95% credible interval (CrI) 0.07 to 0.71] with a specificity of 1.00 (95% CrI 0.97 to 1.00) compared with TOE. The pooled sensitivity to detect left atrial thrombus in three studies using TTEh was 0.79 (95% CrI 0.47 to 0.94) with a specificity of 1.00 (95% CrI 0.99 to 1.00) compared with TOE. The pooled sensitivity to detect PFO in 13 studies using TTEf was 0.34 (95% CrI 0.21 to 0.47) with a specificity of 1.00 (95% CrI 0.99 to 1.00) compared with TOE. The pooled sensitivity to detect PFO in 11 studies using TTEh was 0.89 (95% CrI 0.80 to 0.95) with a specificity of 0.99 (95% CrI 0.97 to 1.00) compared with TOE. The pooled sensitivity to detect spontaneous echo contrast (SEC) in the left atrium in four studies using TTEf was 0.00 (95% CrI 0.00 to 0.02) with a specificity of 1.00 (95% CrI 0.99 to 1.00) compared with TOE. Superior diagnostic accuracy was found using TTEh to detect left atrial SEC, with a sensitivity of 0.88 (95% CrI 0.78 to 0.94) and a specificity of 1.00 (95% CrI 0.03 to 1.00) compared with TOE, although this was based on a single study. Differences in the diagnostic accuracy of TTE and TOE occurred mostly in their sensitivity to detect cardiac sources of stroke; in most studies the specificity of TTE and TOE was similar. No adverse events data were reported.

Our principal economic finding is that TTEh is a cost-effective use of NHS resources compared with TOE in those cases where clinicians deem it the most appropriate form of testing. Because of data limitations we have not evaluated the cost-effectiveness of TOE in those cases in which clinicians regard it the most appropriate test.
The survey of UK stroke units showed that the decision-making process in the management of stroke and TIA is very complex and varies considerably by site. It is clear that to accurately describe current management practice a very sophisticated questionnaire would be required, which may result in poor response rates and thus yield little useful information.

**Discussion**

There was considerable variation in the prevalence of cardiac causes of stroke, reflecting the heterogeneity of the included studies and the uncertainty surrounding the clinical importance of these cardiac pathologies in ischaemic stroke. Data were derived from risk factor findings on routine examination rather than established aetiology, and the relative importance of each of the cardiac pathologies in ischaemic stroke is uncertain.

Across a range of cardiac pathologies (PFO, atrial thrombus, atrial septal defect, atrial septal aneurysm, left atrial appendage thrombus, SEC) the diagnostic accuracy of TTEh was superior to that of TTEf, although the consequence of the improved sensitivity of TTEh was a decrease in specificity. The diagnostic accuracy of TOE was superior to that of TTEh across most cardiac pathologies, although TOE also demonstrated imperfect accuracy for the detection of PFO.

The deterministic and probabilistic economic analyses both show that in those cases in which clinicians consider TTEh to be the most appropriate test it is a cost-effective use of NHS resources. It should be noted that the evidence base for the analysis for some of the main parameters in the model was poor and thus the conclusions reached should be treated with a certain amount of caution.

This analysis has highlighted the need for further evaluation of current echocardiography technologies, the causal associations between potential risk factors and stroke and whether or not anticoagulation therapies prevent recurrent stroke. In the presence of multiple risk factors, establishing the cause of cardioembolic stroke is complex and unlikely to provide an unequivocal answer. Studies attempting to establish the prevalence of cardiac sources of stroke should perform a thorough clinical evaluation to identify all potential risk factors, rule out those that are not relevant and, when possible, grade the findings according to risk. Research is needed to reduce the uncertainty around the estimates of the sensitivity and specificity of TTEh and TOE, singly and in combination, in detecting treatable cardiac abnormalities compared with the ‘gold standard’ in each pathology. Answering these research questions would improve the accuracy of the results produced by the economic model.

**Conclusion**

The economic analysis indicates that, in those cases in which TTEh is deemed the most appropriate test for the management of stroke and TIA, it is a cost-effective use of NHS resources. Because of data limitations it was not possible to evaluate the cost-effectiveness of TTEh compared with TOE in subsets of cases in which TOE is considered most appropriate.

However, this analysis has highlighted the need for more research in several areas and until this is carried out the results of the economic evaluation should be treated with a certain amount of caution. The main research priorities are long-term UK-based studies measuring stroke recurrence rates, the efficacy of treatment and the diagnostic accuracy of TTEh and TOE in detecting cardiac abnormalities that respond to treatment.
Study registration

This study is registered as PROSPERO no. CRD42011001353.

Funding

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.
Criteria for inclusion in the Health Technology Assessment journal
Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme
The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: www.hta.ac.uk/

This report
The research reported in this issue of the journal was funded by the HTA programme as project number 09/68/01. The contractual start date was in February 2010. The draft report began editorial review in February 2012 and was accepted for publication in August 2012. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2014. This work was produced by Holmes et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Editor-in-Chief of Health Technology Assessment and NIHR Journals Library

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Professor Aileen Clarke  Professor of Health Sciences, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson  Director of NETSCC, HTA, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Dr Tom Marshall  Reader in Primary Care, School of Health and Population Sciences, University of Birmingham, UK

Professor Elaine McColl  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Honorary Professor, Business School, Winchester University and Medical School, University of Warwick, UK

Professor Jane Norman  Professor of Maternal and Fetal Health, University of Edinburgh, UK

Professor John Powell  Consultant Clinical Adviser, NICE, UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professorial Research Associate, University College London, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk